SSRI differentiation: Pharmacology and pharmacokinetics

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Pharmacy

Background:

• Antidepressant acute pharmacology primarily involves presynaptic action.
• Therapeutic effects are linked to adaptive postsynaptic changes in monoaminergic neurons.
• Selective serotonin reuptake inhibitors (SSRIs) represent a major class of antidepressants.

Purpose of the Study:

• To compare the pharmacological and pharmacokinetic profiles of various SSRIs.
• To highlight differences in receptor affinity, metabolism, and clinical suitability.
• To inform clinicians about potential drug interactions involving SSRIs and cytochrome P450 enzymes.

Main Methods:

• Comparative analysis of SSRI pharmacology.
• Review of pharmacokinetic data, including metabolism and protein binding.
• Examination of SSRI interactions with neurotransmitter receptors and cytochrome P450 enzymes.

Main Results:

• SSRI potency in serotonin reuptake inhibition does not correlate with clinical dosage.
• Individual SSRIs exhibit varying affinities for muscarinic cholinergic and histamine-H1 receptors, potentially causing side effects.
• Differences in metabolism (e.g., active metabolites like norfluoxetine), protein binding, absorption, and suitability for special populations were observed.
• Cytochrome P450 inhibition varies among SSRIs, with potential for drug interactions.

Conclusions:

• Significant pharmacological and pharmacokinetic differences exist among SSRIs, influencing their clinical application and side effect profiles.
• Awareness of these variations is essential for optimizing antidepressant therapy.
• Clinicians should be informed about potential drug interactions, particularly concerning cytochrome P450 metabolism.